{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:06:53Z","timestamp":1772896013904,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s13730-020-00444-2","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T08:02:47Z","timestamp":1579161767000},"page":"141-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARM\u03b1), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-7661","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"444_CR1","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1053\/j.ajkd.2015.05.011","volume":"66","author":"K Tsuruya","year":"2015","unstructured":"Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, Fujimoto S, Konta T, Moriyama T, Yamagata K, Narita I, Kimura K, Kondo M, Asahi K, Kurahashi I, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972\u201383.","journal-title":"Am J Kidney Dis"},{"key":"444_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","volume":"54","author":"TM Davis","year":"2011","unstructured":"Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kes\u00e4niemi YA, Gebski VJ, Scott RS, Keech AC, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54:280\u201390.","journal-title":"Diabetologia"},{"key":"444_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5551\/jat.48918","volume":"26","author":"S Yamashita","year":"2019","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPARalpha modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb. 2019;26:389\u2013402.","journal-title":"J Atheroscler Thromb."},{"key":"444_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/ijms20030706","volume":"20","author":"K Yokote","year":"2019","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S, Of The KSGOB. Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMalpha), in dyslipidemic patients with renal impairment. Int J Mol Sci. 2019;20:706.","journal-title":"Int J Mol Sci"},{"key":"444_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.metabol.2017.02.013","volume":"71","author":"T Maki","year":"2017","unstructured":"Maki T, Maeda Y, Sonoda N, Makimura H, Kimura S, Maeno S, Takayanagi R, Inoguchi T. Renoprotective effect of a novel selective PPARalpha modulator K-877 in db\/db mice: a role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway. Metabolism. 2017;71:33\u201345.","journal-title":"Metabolism"},{"key":"444_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.5301\/jn.5000151","volume":"26","author":"T Kawamura","year":"2013","unstructured":"Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, Matsushima M, Yoshimura M, Horikoshi S, Suzuki Y, Furusu A, Yasuda T, Shirai S, Shibata T, Endoh M, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2013;26:350\u20137.","journal-title":"J Nephrol."},{"key":"444_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J, IgAN Classification Working Group of the International IgA Nephropathy Network, and the Renal Pathology Society; Conference Participants. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91:1014\u201321.","journal-title":"Kidney Int"},{"key":"444_CR8","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transpl. 2009;24:3694\u2013701.","journal-title":"Nephrol Dial Transpl"},{"key":"444_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"444_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0272-6386(04)01082-0","volume":"44","author":"M Tonelli","year":"2004","unstructured":"Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004;44:832\u20139.","journal-title":"Am J Kidney Dis"},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1291\/hypres.27.417","volume":"27","author":"K Sato","year":"2004","unstructured":"Sato K, Sugawara A, Kudo M, Uruno A, Ito S, Takeuchi K. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertens Res. 2004;27:417\u201325.","journal-title":"Hypertens Res."},{"key":"444_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","volume":"249","author":"N Hennuyer","year":"2016","unstructured":"Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, Colin S, Vallez E, Lestavel S, Lefebvre P, Staels B. The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis. 2016;249:200\u20138.","journal-title":"Atherosclerosis"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00444-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-020-00444-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00444-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T02:06:57Z","timestamp":1610676417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-020-00444-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00444-2","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,16]]},"assertion":[{"value":"31 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AT has received a research grant from GlaxoSmithKline. KN has received honoraria from Ono, Takeda, Daiichi Sankyo, Astellas, MSD, Boehringer Ingelheim, and Mitsubishi Tanabe; research grants from Asahi Kasei, Astellas, Boehringer Ingelheim, Mitsubishi Tanabe, Teijin, and Terumo; scholarship from Bayer, Takeda, Astellas, Daiichi Sankyo, Teijin, and Bristol-Myers Squibb. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the participant included in the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}